Loading…

Activation of cGAS-STING Signal to Inhibit the Proliferation of Bladder Cancer: The Immune Effect of Cisplatin

Cisplatin is commonly used in neoadjuvant, adjuvant, and systemic therapy for advanced bladder cancer, but its immune-related mechanism is still unclear. Exploration of the immune effects of cisplatin in bladder cancer would complement the comprehensive mechanism of cisplatin and provide the basis f...

Full description

Saved in:
Bibliographic Details
Published in:Cells (Basel, Switzerland) Switzerland), 2022-09, Vol.11 (19), p.3011
Main Authors: Fu, Guanghou, Wu, Yunfei, Zhao, Guanan, Chen, Xiaoyi, Xu, Zhijie, Sun, Junjie, Tian, Junjie, Cheng, Zhengjun, Shi, Yue, Jin, Baiye
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c525t-634399a7d5e3d34a937aad1367bba3472352d3cb1a0b5b52d9b19cda39e6334b3
cites cdi_FETCH-LOGICAL-c525t-634399a7d5e3d34a937aad1367bba3472352d3cb1a0b5b52d9b19cda39e6334b3
container_end_page
container_issue 19
container_start_page 3011
container_title Cells (Basel, Switzerland)
container_volume 11
creator Fu, Guanghou
Wu, Yunfei
Zhao, Guanan
Chen, Xiaoyi
Xu, Zhijie
Sun, Junjie
Tian, Junjie
Cheng, Zhengjun
Shi, Yue
Jin, Baiye
description Cisplatin is commonly used in neoadjuvant, adjuvant, and systemic therapy for advanced bladder cancer, but its immune-related mechanism is still unclear. Exploration of the immune effects of cisplatin in bladder cancer would complement the comprehensive mechanism of cisplatin and provide the basis for combination therapy of cisplatin and immunotherapy in bladder cancer. We confirmed the immune effects of cisplatin on T24 and TCCSUP bladder cancer cell lines in vitro and explored the important function of these immune effects in the bladder cancer microenvironment in a mice tumor model. We found cisplatin induced immune response in bladder cancer by RNA sequencing and validated that cGAS-STING signal was deeply involved in this response. Cisplatin induced cGAS-STING signal inhibited the proliferation of bladder cancer and increased the infiltration percentages of CD8+ T cells and dendritic cells in a transplantation mice tumor model. Accumulation of dsDNA and the release of chromatin bound cGAS are important to activate downstream STING. Our findings indicated a cisplatin-related immune effect in bladder cancer, and cisplatin combined with immunotherapy might have a synergistic effect for bladder cancer therapy.
doi_str_mv 10.3390/cells11193011
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_54a8fee49df3435ab3f76ec02da86ec5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A745409952</galeid><doaj_id>oai_doaj_org_article_54a8fee49df3435ab3f76ec02da86ec5</doaj_id><sourcerecordid>A745409952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-634399a7d5e3d34a937aad1367bba3472352d3cb1a0b5b52d9b19cda39e6334b3</originalsourceid><addsrcrecordid>eNptkk1vEzEQhlcIRKvSI_eVuHDZYnvs3ZgDUohKiFQBUsLZmvVH4mjXDt5Npf57vE1VCMI-zGj8vO9oNC6Kt5TcAEjyQduuGyilEgilL4pLRhqoOCfy5V_5RXE9DHuSz4zWlIjXxQXUDIhs2GUR5nr09zj6GMroSr2cr6v1ZvVtWa79NmBXjrFchZ1v_ViOO1v-SLHzzqZnxecOjbGpXGDQNn0sNxla9f0x2PLWOavHCVr44dBlSXhTvHLYDfb6KV4VP7_cbhZfq7vvy9VifldpwcRY1cBBSmyMsGCAo4QG0VCom7ZF4A0DwQzoliJpRZtz2VKpDYK0NQBv4apYnXxNxL06JN9jelARvXosxLRVmEavO6sEx5mzlkvjcleBLbimtpowg7McRfb6dPI6HNveGm3DmLA7Mz1_CX6ntvFeSVFzgMng_ZNBir-OdhhV74dpdRhsPA6KNUzkFQKnGX33D7qPx5T38EhxRptazP5QW8wD-OBi7qsnUzVvuMg7l4Jl6uY_VL7G9l7HYJ3P9TNBdRLoFIchWfc8IyVq-m_q7L_Bb8YDxOU</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2724217658</pqid></control><display><type>article</type><title>Activation of cGAS-STING Signal to Inhibit the Proliferation of Bladder Cancer: The Immune Effect of Cisplatin</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Fu, Guanghou ; Wu, Yunfei ; Zhao, Guanan ; Chen, Xiaoyi ; Xu, Zhijie ; Sun, Junjie ; Tian, Junjie ; Cheng, Zhengjun ; Shi, Yue ; Jin, Baiye</creator><creatorcontrib>Fu, Guanghou ; Wu, Yunfei ; Zhao, Guanan ; Chen, Xiaoyi ; Xu, Zhijie ; Sun, Junjie ; Tian, Junjie ; Cheng, Zhengjun ; Shi, Yue ; Jin, Baiye</creatorcontrib><description>Cisplatin is commonly used in neoadjuvant, adjuvant, and systemic therapy for advanced bladder cancer, but its immune-related mechanism is still unclear. Exploration of the immune effects of cisplatin in bladder cancer would complement the comprehensive mechanism of cisplatin and provide the basis for combination therapy of cisplatin and immunotherapy in bladder cancer. We confirmed the immune effects of cisplatin on T24 and TCCSUP bladder cancer cell lines in vitro and explored the important function of these immune effects in the bladder cancer microenvironment in a mice tumor model. We found cisplatin induced immune response in bladder cancer by RNA sequencing and validated that cGAS-STING signal was deeply involved in this response. Cisplatin induced cGAS-STING signal inhibited the proliferation of bladder cancer and increased the infiltration percentages of CD8+ T cells and dendritic cells in a transplantation mice tumor model. Accumulation of dsDNA and the release of chromatin bound cGAS are important to activate downstream STING. Our findings indicated a cisplatin-related immune effect in bladder cancer, and cisplatin combined with immunotherapy might have a synergistic effect for bladder cancer therapy.</description><identifier>ISSN: 2073-4409</identifier><identifier>EISSN: 2073-4409</identifier><identifier>DOI: 10.3390/cells11193011</identifier><identifier>PMID: 36230972</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Bladder cancer ; Cancer ; CD8 antigen ; Cellular signal transduction ; cGAS-STING ; Chemotherapy ; Chromatin ; chromatin bound ; Cisplatin ; Dendritic cells ; DNA damage ; Dosage and administration ; Drug therapy ; Experiments ; Gene expression ; Health aspects ; Immunotherapy ; Lymphocytes T ; Metastases ; Microenvironments ; Patient outcomes ; Transplantation ; Tumor cell lines ; Tumors</subject><ispartof>Cells (Basel, Switzerland), 2022-09, Vol.11 (19), p.3011</ispartof><rights>COPYRIGHT 2022 MDPI AG</rights><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-634399a7d5e3d34a937aad1367bba3472352d3cb1a0b5b52d9b19cda39e6334b3</citedby><cites>FETCH-LOGICAL-c525t-634399a7d5e3d34a937aad1367bba3472352d3cb1a0b5b52d9b19cda39e6334b3</cites><orcidid>0000-0002-6667-0424 ; 0000-0003-4243-3894</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2724217658/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2724217658?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids></links><search><creatorcontrib>Fu, Guanghou</creatorcontrib><creatorcontrib>Wu, Yunfei</creatorcontrib><creatorcontrib>Zhao, Guanan</creatorcontrib><creatorcontrib>Chen, Xiaoyi</creatorcontrib><creatorcontrib>Xu, Zhijie</creatorcontrib><creatorcontrib>Sun, Junjie</creatorcontrib><creatorcontrib>Tian, Junjie</creatorcontrib><creatorcontrib>Cheng, Zhengjun</creatorcontrib><creatorcontrib>Shi, Yue</creatorcontrib><creatorcontrib>Jin, Baiye</creatorcontrib><title>Activation of cGAS-STING Signal to Inhibit the Proliferation of Bladder Cancer: The Immune Effect of Cisplatin</title><title>Cells (Basel, Switzerland)</title><description>Cisplatin is commonly used in neoadjuvant, adjuvant, and systemic therapy for advanced bladder cancer, but its immune-related mechanism is still unclear. Exploration of the immune effects of cisplatin in bladder cancer would complement the comprehensive mechanism of cisplatin and provide the basis for combination therapy of cisplatin and immunotherapy in bladder cancer. We confirmed the immune effects of cisplatin on T24 and TCCSUP bladder cancer cell lines in vitro and explored the important function of these immune effects in the bladder cancer microenvironment in a mice tumor model. We found cisplatin induced immune response in bladder cancer by RNA sequencing and validated that cGAS-STING signal was deeply involved in this response. Cisplatin induced cGAS-STING signal inhibited the proliferation of bladder cancer and increased the infiltration percentages of CD8+ T cells and dendritic cells in a transplantation mice tumor model. Accumulation of dsDNA and the release of chromatin bound cGAS are important to activate downstream STING. Our findings indicated a cisplatin-related immune effect in bladder cancer, and cisplatin combined with immunotherapy might have a synergistic effect for bladder cancer therapy.</description><subject>Bladder cancer</subject><subject>Cancer</subject><subject>CD8 antigen</subject><subject>Cellular signal transduction</subject><subject>cGAS-STING</subject><subject>Chemotherapy</subject><subject>Chromatin</subject><subject>chromatin bound</subject><subject>Cisplatin</subject><subject>Dendritic cells</subject><subject>DNA damage</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Experiments</subject><subject>Gene expression</subject><subject>Health aspects</subject><subject>Immunotherapy</subject><subject>Lymphocytes T</subject><subject>Metastases</subject><subject>Microenvironments</subject><subject>Patient outcomes</subject><subject>Transplantation</subject><subject>Tumor cell lines</subject><subject>Tumors</subject><issn>2073-4409</issn><issn>2073-4409</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1vEzEQhlcIRKvSI_eVuHDZYnvs3ZgDUohKiFQBUsLZmvVH4mjXDt5Npf57vE1VCMI-zGj8vO9oNC6Kt5TcAEjyQduuGyilEgilL4pLRhqoOCfy5V_5RXE9DHuSz4zWlIjXxQXUDIhs2GUR5nr09zj6GMroSr2cr6v1ZvVtWa79NmBXjrFchZ1v_ViOO1v-SLHzzqZnxecOjbGpXGDQNn0sNxla9f0x2PLWOavHCVr44dBlSXhTvHLYDfb6KV4VP7_cbhZfq7vvy9VifldpwcRY1cBBSmyMsGCAo4QG0VCom7ZF4A0DwQzoliJpRZtz2VKpDYK0NQBv4apYnXxNxL06JN9jelARvXosxLRVmEavO6sEx5mzlkvjcleBLbimtpowg7McRfb6dPI6HNveGm3DmLA7Mz1_CX6ntvFeSVFzgMng_ZNBir-OdhhV74dpdRhsPA6KNUzkFQKnGX33D7qPx5T38EhxRptazP5QW8wD-OBi7qsnUzVvuMg7l4Jl6uY_VL7G9l7HYJ3P9TNBdRLoFIchWfc8IyVq-m_q7L_Bb8YDxOU</recordid><startdate>20220927</startdate><enddate>20220927</enddate><creator>Fu, Guanghou</creator><creator>Wu, Yunfei</creator><creator>Zhao, Guanan</creator><creator>Chen, Xiaoyi</creator><creator>Xu, Zhijie</creator><creator>Sun, Junjie</creator><creator>Tian, Junjie</creator><creator>Cheng, Zhengjun</creator><creator>Shi, Yue</creator><creator>Jin, Baiye</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6667-0424</orcidid><orcidid>https://orcid.org/0000-0003-4243-3894</orcidid></search><sort><creationdate>20220927</creationdate><title>Activation of cGAS-STING Signal to Inhibit the Proliferation of Bladder Cancer: The Immune Effect of Cisplatin</title><author>Fu, Guanghou ; Wu, Yunfei ; Zhao, Guanan ; Chen, Xiaoyi ; Xu, Zhijie ; Sun, Junjie ; Tian, Junjie ; Cheng, Zhengjun ; Shi, Yue ; Jin, Baiye</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-634399a7d5e3d34a937aad1367bba3472352d3cb1a0b5b52d9b19cda39e6334b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Bladder cancer</topic><topic>Cancer</topic><topic>CD8 antigen</topic><topic>Cellular signal transduction</topic><topic>cGAS-STING</topic><topic>Chemotherapy</topic><topic>Chromatin</topic><topic>chromatin bound</topic><topic>Cisplatin</topic><topic>Dendritic cells</topic><topic>DNA damage</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Experiments</topic><topic>Gene expression</topic><topic>Health aspects</topic><topic>Immunotherapy</topic><topic>Lymphocytes T</topic><topic>Metastases</topic><topic>Microenvironments</topic><topic>Patient outcomes</topic><topic>Transplantation</topic><topic>Tumor cell lines</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fu, Guanghou</creatorcontrib><creatorcontrib>Wu, Yunfei</creatorcontrib><creatorcontrib>Zhao, Guanan</creatorcontrib><creatorcontrib>Chen, Xiaoyi</creatorcontrib><creatorcontrib>Xu, Zhijie</creatorcontrib><creatorcontrib>Sun, Junjie</creatorcontrib><creatorcontrib>Tian, Junjie</creatorcontrib><creatorcontrib>Cheng, Zhengjun</creatorcontrib><creatorcontrib>Shi, Yue</creatorcontrib><creatorcontrib>Jin, Baiye</creatorcontrib><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cells (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fu, Guanghou</au><au>Wu, Yunfei</au><au>Zhao, Guanan</au><au>Chen, Xiaoyi</au><au>Xu, Zhijie</au><au>Sun, Junjie</au><au>Tian, Junjie</au><au>Cheng, Zhengjun</au><au>Shi, Yue</au><au>Jin, Baiye</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activation of cGAS-STING Signal to Inhibit the Proliferation of Bladder Cancer: The Immune Effect of Cisplatin</atitle><jtitle>Cells (Basel, Switzerland)</jtitle><date>2022-09-27</date><risdate>2022</risdate><volume>11</volume><issue>19</issue><spage>3011</spage><pages>3011-</pages><issn>2073-4409</issn><eissn>2073-4409</eissn><abstract>Cisplatin is commonly used in neoadjuvant, adjuvant, and systemic therapy for advanced bladder cancer, but its immune-related mechanism is still unclear. Exploration of the immune effects of cisplatin in bladder cancer would complement the comprehensive mechanism of cisplatin and provide the basis for combination therapy of cisplatin and immunotherapy in bladder cancer. We confirmed the immune effects of cisplatin on T24 and TCCSUP bladder cancer cell lines in vitro and explored the important function of these immune effects in the bladder cancer microenvironment in a mice tumor model. We found cisplatin induced immune response in bladder cancer by RNA sequencing and validated that cGAS-STING signal was deeply involved in this response. Cisplatin induced cGAS-STING signal inhibited the proliferation of bladder cancer and increased the infiltration percentages of CD8+ T cells and dendritic cells in a transplantation mice tumor model. Accumulation of dsDNA and the release of chromatin bound cGAS are important to activate downstream STING. Our findings indicated a cisplatin-related immune effect in bladder cancer, and cisplatin combined with immunotherapy might have a synergistic effect for bladder cancer therapy.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>36230972</pmid><doi>10.3390/cells11193011</doi><orcidid>https://orcid.org/0000-0002-6667-0424</orcidid><orcidid>https://orcid.org/0000-0003-4243-3894</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2073-4409
ispartof Cells (Basel, Switzerland), 2022-09, Vol.11 (19), p.3011
issn 2073-4409
2073-4409
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_54a8fee49df3435ab3f76ec02da86ec5
source Publicly Available Content Database; PubMed Central
subjects Bladder cancer
Cancer
CD8 antigen
Cellular signal transduction
cGAS-STING
Chemotherapy
Chromatin
chromatin bound
Cisplatin
Dendritic cells
DNA damage
Dosage and administration
Drug therapy
Experiments
Gene expression
Health aspects
Immunotherapy
Lymphocytes T
Metastases
Microenvironments
Patient outcomes
Transplantation
Tumor cell lines
Tumors
title Activation of cGAS-STING Signal to Inhibit the Proliferation of Bladder Cancer: The Immune Effect of Cisplatin
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T03%3A07%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activation%20of%20cGAS-STING%20Signal%20to%20Inhibit%20the%20Proliferation%20of%20Bladder%20Cancer:%20The%20Immune%20Effect%20of%20Cisplatin&rft.jtitle=Cells%20(Basel,%20Switzerland)&rft.au=Fu,%20Guanghou&rft.date=2022-09-27&rft.volume=11&rft.issue=19&rft.spage=3011&rft.pages=3011-&rft.issn=2073-4409&rft.eissn=2073-4409&rft_id=info:doi/10.3390/cells11193011&rft_dat=%3Cgale_doaj_%3EA745409952%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c525t-634399a7d5e3d34a937aad1367bba3472352d3cb1a0b5b52d9b19cda39e6334b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2724217658&rft_id=info:pmid/36230972&rft_galeid=A745409952&rfr_iscdi=true